Platelet aggregation and PF3 availability induced by platelet antibodies in thromboasthenia.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D000906:Antibodies; D000961:Antilymphocyte Serum / Q000494:pharmacology; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000151:congenital; D001779:Blood Coagulation Factors / Q000378:metabolism; D001792:Blood Platelets / Q000166:cytology / Q000276:immunology* / Q000378:metabolism / Q000502:physiology; D002462:Cell Membrane / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006736:Horses / Q000276:immunology; D006801:Humans; D007106:Immune Sera; D008074:Lipoproteins / Q000378:metabolism; D008855:Microscopy, Electron, Scanning; D010973:Platelet Adhesiveness / Q000187:drug effects; D013917:Thrombin / Q000494:pharmacology; D013997:Time Factors
D000906:Antibodies; D000961:Antilymphocyte Serum; D001779:Blood Coagulation Factors; D007106:Immune Sera; D008074:Lipoproteins; D000244:Adenosine Diphosphate; D003094:Collagen; D013917:Thrombin; D004837:Epinephrine